KUALA LUMPUR, March 9 -- Adagene Inc (Adagene) has announced publication of four abstracts featuring preclinical data from its expanding pipeline in advance of the AACR Annual Meeting 2022 in New Orleans, Louisiana from April 8-13, 2022.
The full abstracts are available on the AACR meeting website, according to a statement.
At AACR, presentations will include preclinical results showing the potential best-in-class profiles for three differentiated preclinical product candidates in IND-enabling studies: ADG138, ADG206 and ADG153.
The fourth presentation introduces a new capability for the company’s proprietary bispecific T-cell engagers (TCEs) with CD28.
“These presentations highlight the promise of our AI-driven technology platform to build a deep, broad, and differentiated pipeline of transformative antibody therapeutics,” said Co-founder, Chief Executive Officer and Chairman of Adagene, Peter Luo, Ph.D.
“We are designing safe and effective antibody candidates across the cancer immunity cycle, including our POWERbody approach, which integrates the SAFEbody technology with multiple antibody-based modalities."
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.
More details at https://investor.adagene.com.
-- BERNAMA
No comments:
Post a Comment